Market Signal Briefing

CRH (CRH - Free Report) ended the recent trading session at $117.85, demonstrating a +1.3% change from the preceding day's closing price. This change outpaced the S&P 500's 0.58% gain on the day.

Coming into today, shares of the building material company had gained 5.08% in the past month. In that same time, the Construction sector lost 3.22%, while the S&P 500 gained 3.68%.

Market participants will be closely following the financial results of CRH in its upcoming release. The company is forecasted to report an EPS of $2.18, showcasing a 15.96% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $11.24 billion, indicating a 6.9% growth compared to the corresponding quarter of the prior year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.57 per share and a revenue of $37.74 billion, representing changes of +3.34% and +6.1%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for CRH. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.92% lower. CRH is holding a Zacks Rank of #3 (Hold) right now.

Looking at its valuation, CRH is holding a Forward P/E ratio of 20.88. Its industry sports an average Forward P/E of 19.43, so one might conclude that CRH is trading at a premium comparatively.

One should further note that CRH currently holds a PEG ratio of 1.65. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Building Products - Miscellaneous industry stood at 1.86 at the close of the market yesterday.

The Building Products - Miscellaneous industry is part of the Construction sector. This group has a Zacks Industry Rank of 154, putting it in the bottom 38% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

In the latest close session, VirTra, Inc. (VTSI - Free Report) was up +2.13% at $6.23. This move outpaced the S&P 500's daily gain of 0.58%.

The company's stock has climbed by 6.83% in the past month, exceeding the Aerospace sector's gain of 5.47% and the S&P 500's gain of 3.68%.

The investment community will be paying close attention to the earnings performance of VirTra, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.05, reflecting no change from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.48 million, showing steadiness compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.33 per share and a revenue of $29.79 million, signifying shifts of +175% and +10.12%, respectively, from the last year.

It's also important for investors to be aware of any recent modifications to analyst estimates for VirTra, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. VirTra, Inc. presently features a Zacks Rank of #3 (Hold).

In the context of valuation, VirTra, Inc. is at present trading with a Forward P/E ratio of 18.49. This expresses no noticeable deviation compared to the average Forward P/E of 18.49 of its industry.

The Electronics - Military industry is part of the Aerospace sector. At present, this industry carries a Zacks Industry Rank of 94, placing it within the top 39% of over 250 industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Inventiva S.A. (NASDAQ:IVA) Analyst/Investor Day October 8, 2025 11:30 AM EDT

Company Participants

Mark Pruzanski
Andrew Obenshain - CEO & Director
Jason Campagna - President of Research and Development & Chief Medical Officer
Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance

Conference Call Participants

William Alazawi
Arun Sanyal
Nezam H. Afdhal
Henry E. Chang
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Ritu Baral - TD Cowen, Research Division
Edward Nash - Canaccord Genuity Corp., Research Division
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division
Rami Katkhuda - LifeSci Capital, LLC, Research Division
Antonio Arce - WestPark Capital, Inc., Research Division

Presentation

Mark Pruzanski

Okay. Why don't we kick things off. Hi, everyone. I'm Mark Pruzanski, I'm the Chairman of the Board of Inventiva and welcome to our investor event. We're going to be telling you today about the next and hopefully best-in-category oral therapy to get to patients with MASH, lanifibranor. We're going to be making forward-looking statements. Here's the agenda.

It's going to be pretty packed, and I'm going to get out of your way and introduce you to Andrew in a minute followed by 3 well-known, key opinion-leading hepatologists in the MASH space. And then we will a panel discussion with some of the senior management team and time for Q&A at the end. So I've been involved with Inventiva for the better part of the year. And it's been a momentous year. All of you know that we just about a year ago raised a $400-plus million pipe, which positioned the company very well with respect to the enrollment of the global Phase III NATiV3 trial.

We double-clicked to accelerate enrollment and over enrolled the study, which we announced in April of this year. And then

Recommended For You

OKLAHOMA CITY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Murphy Law Firm is investigating claims on behalf of all individuals whose personal and confidential information was compromised in the data breach involving AppFolio, Inc. To join the class action lawsuit, visit our site HERE.

On or around August 22, 2025, AppFolio, Inc. (“AppFolio”) became aware of a security incident affecting Salesloft, a provider of sales enablement software and one of AppFolio’s vendors. Based on a subsequent forensic investigation, AppFolio determined that cybercriminals infiltrated this inadequately secured network and gained access to AppFolio’s files. The investigation further determined that, through this infiltration, cybercriminals accessed and/or acquired files containing the sensitive personal information of tens of thousands of individuals.

The information exposed in the data breach includes, but is not limited to:

NamesSocial Security numbers If you received notice of the AppFolio and Salesloft data breach or if your personal information was compromised in the breach, please visit our site HERE. Murphy Law Firm is evaluating legal options, including a potential class action lawsuit, to recover damages on behalf of individuals who were affected by the AppFolio data breach.

As a result of the data breach, these individuals’ personal and highly sensitive information may be in the hands of cybercriminals who can place the information for sale on the dark web or use the information to perpetrate identity theft.

To join a class action lawsuit, click HERE

Murphy Law Firm specializes in data breach class actions, consumer class actions, and federal securities class actions. The firm has extensive experience in securing highly favorable recoveries for its clients.

Contact:
Murphy Law Firm
[email protected]

Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression

, /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new data for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) will be highlighted at the upcoming American Academy of Ophthalmology Annual Meeting (AAO 2025), October 18-20, in Orlando, Fla.

The data feature long-term safety and efficacy results from the GATHER2 open-label extension study, real-world evidence on treatment patterns and safety of IZERVAY in the U.S., and the latest findings on a structure-function link in GA via ellipsoid zone integrity and low-luminance deficit.

Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma
"Astellas continues to advance understanding of geographic atrophy (GA) through new data that deepen insights into disease progression and treatment. We are committed to partnering with the retina community to continue driving innovation that improves outcomes for patients with GA."

Overview of Astellas Presentations at AAO 2025

Presentation Title

Presenter

Presentation Details

Avacincaptad Pegol for GA: 3-year
Results from the GATHER2 Open-Label
Extension Trial

A. Khanani     

Type: Oral

Presentation Number: TBD

Date: Oct 17, 2025

4:58-5:05 PM ET

Treatment Patterns and Safety of
Avacincaptad Pegol in Real-World
Patients With GA

D. Borkar

Type: Poster Panel Discussion

Poster Number: PO078

Date: Oct 17, 2025

2:30-3:00 PM ET

Structure‒Function Link of Ellipsoid Zone
Integrity and Low Luminance Deficit in
Avacincaptad Pegol-Treated Eyes With
Geographic Atrophy

R. Downes

Type: On Demand Poster

Poster Number: PO696

IZERVAY is approved for the treatment of GA in the United States and Japan, and remains investigational in other countries and regions.

About IZERVAY™ (avacincaptad pegol intravitreal solution)

IMPORTANT SAFETY INFORMATION AND USE

Do NOT receive IZERVAY if you: 

Have an infection in or around your eye 
Have active swelling in or around your eye that may include pain and redness 

IZERVAY can cause serious side effects: 

Eye injections like the one for IZERVAY can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). 
Call your healthcare provider right away if you have redness of the eye, eye pain, increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small specks floating in your vision, flashes of light, or increased sensitivity to light. 
There is a risk of developing wet AMD with IZERVAY. You should report any symptoms (visual distortions such as straight lines seeming bent, deterioration in vision, dark spots, loss of central vision) to your healthcare provider to monitor. 
IZERVAY may cause a temporary increase in eye pressure after the injection. Your healthcare provider will monitor this after each injection. 

Before receiving IZERVAY tell your healthcare provider about all of your medical conditions including if you: 

Have a history of seeing flashes of light or small specks floating in your vision and if you have a sudden increase of size and number of these specks. 
Have high pressure in the eye or if you have glaucoma. 
Are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about any medicine you take. 

What should I avoid while receiving IZERVAY? 

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently. 

What are the most common side effects of IZERVAY? 

Blood in the white of the eye 
Increase in eye pressure 
Blurred vision 
Wet age-related macular degeneration 

These are not all the possible side effects of IZERVAY. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.

What is IZERVAY™?
IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD). 

About Geographic Atrophy
Age-related macular degeneration (AMD) is the major cause of moderate and severe loss of central vision in aging adults, affecting both eyes in the majority of patients. The macula is a small area in the central portion of the retina responsible for central vision. As AMD progresses, the loss of retinal cells and the underlying blood vessels in the macula results in marked thinning and/or atrophy of retinal tissue. Geographic atrophy, associated with AMD, leads to further irreversible loss of vision in these patients.

About the GATHER Clinical Trials
IZERVAY met its primary endpoint in the GATHER1 (NCT02686658) clinical trial and the GATHER2 (NCT04435366) clinical trial, both of which were randomized, double-masked, sham-controlled, multicenter Phase 3 clinical trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1 and 448 participants enrolled in GATHER2. The primary efficacy endpoints in both pivotal studies were based on GA area measured by fundus autofluorescence at three time points: baseline, month 6, and month 12. Safety was evaluated in over 700 patients with GA across the two trials.

In year 2 of the GATHER2 study, patients treated with IZERVAY in year 1 were re-randomized to receive either IZERVAY dosed monthly (EM, n=96) or every other month (EOM, n=93); patients who received sham in year 1 continued to receive sham in year 2 (n=203).

About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

SOURCE Astellas Pharma Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Key Takeaways The 2025 Wall Street narrative has shifted dramatically from panic to bubble fears.Legendary investor Paul Tudor Jones made headlines when he compared the 2025 market to 1999.A rate cut with stocks at highs, muted sentiment, and further AI expansion suggest a market with legs.
2025 is a prime example of how dynamic the Wall Street narrative can be and how price action can change that narrative. A mere six months ago, Wall Street was in panic mode as President Trump unveiled his ‘Liberation Day’ tariff policy, an economic strategy an American President had not attempted in a century. At the time, many Wall Street investors viewed President Trump’s tariffs as economic suicide, with some even predicting that another “Black Monday” would occur (referring to the day the S&P 500 Index dropped 20% in a single day on October 19, 1987).

Fast forward to the present day, and the Nasdaq Composite is up 50% over the past six months, driven by AI enthusiasm. Today, the Wall Street narrative has done a 180-degree turn from market crash fears to market bubble fears. Let’s use the internet bubble as a potential precedent to explore the current market environment and determine where we stand:

Paul Tudor Jones 1999 Bombshell Comparison

In a recent interview on CNBC’s ‘Squawk Box,’ billionaire and legendary investor Paul Tudor Jones dropped a bombshell, saying that the current market “feels exactly like 1999” and that “investors need to position themselves like it’s October 1999.” If Paul Tudor Jones’ analysis is correct, there is plenty of meat left on the bone for tech investors as the Nasdaq doubled from 1999 to 2000. Not only does Tudor Jones see the 2025 market similar to 1999, but he also believes the current market may end up being more powerful.

Image Source: TradingView

The 1999/2025 Market PrecedentPaul Tudor Jones is no stranger to using market precedents to make bold market predictions. In 1987, he famously predicted the “Black Monday” crash by utilizing an overlay chart that compared the 1987 market to 1929. After shorting the market, a young Paul Tudor Jones and his firm returned 125% in 1987, netting approximately $100 million. Overlay a 1999 and 2025 chart, and the price action looks eerily similar.

Image Source: BarChart

Meanwhile, the current bull market (which started after the tariff madness dissipated) is only a handful of months old. Historically, the average bull market is ~4 years.

Interest Rate Cuts at New Highs = Rocket FuelBeyond the hype surrounding AI, the Federal Reserve is adding fuel to the fire. At the last Fed meeting, Chair Jerome Powell cut interest rates as the S&P 500 reached a new high. The Federal Reserve has cut interest rates 12 times when the S&P 500 Index was within 1% of its all-time high. The market was higher one year later all 12 times, with a median return of 15%, according to JPMorgan ((JPM - Free Report) ) research.

Image Source: Carson Investment Research, @ryandetrick

AI: Beyond LLMs and into the Software LayerUntil now, most AI performance has been concentrated among semiconductor players like Advanced Micro Devices ((AMD - Free Report) ), infrastructure providers like CoreWeave ((CRWV - Free Report) ), and data center energy companies like Bloom Energy ((BE - Free Report) ). However, AI winners are beginning to proliferate from pure-play stocks into other tech areas, such as software stocks. For instance, Figma ((FIG - Free Report) ) and Shopify ((SHOP - Free Report) ) are rising this week after signing deals with OpenAI, the parent company of ChatGPT. The FIG/OpenAI integration will enable users to design tasks with ChatGPT conversations. Meanwhile, SHOP’s partnership will allow ChatGPT users to bypass the traditional e-commerce journey and purchase products straight from the LLM. This collaboration positions Shopify merchants to reach a vast new audience and capitalize on the growing field of conversational commerce.

Animal Spirits Yes, Euphoria NoAny time stocks are up 50% in six months, it’s hard for investors to argue that the animal spirits have been unleashed. Nevertheless, several data points suggest that the current market is far from euphoric. For instance, according to the AAII Sentiment Survey, investor sentiment is not overheated. Bullish sentiment stands at 42.9%, neutral sentiment at 17.9%, and bearish sentiment remains elevated at 39.2%.

Image Source: AAII

Additionally, there is a substantial amount of “dry powder” on the sidelines, with a record $7 trillion in low-risk money market funds. As stocks continue to rise, investors are likely to suffer from “the fear of missing out,” eventually removing funds from these safe havens and into the stock market, adding fuel to the fire.

Valuations are High but Likely to Stretch HigherA key concern among investors is that 2025 valuations are too rich. While the S&P’s current P/E ratio of 23x is elevated compared to historical norms, it pales in comparison to the 2000 peak, which exceeded 40x. Investors must understand that Wall Street is willing to pay higher valuations for high-tech, innovative companies like the current AI leaders.

Image Source: Robert Shiller

Bottom Line

The 2025 bull market is unusually bullish. Although stocks experienced a tremendous run since the ‘Liberation Day’ lows, several key data points suggest that the Nasdaq could still double from here.

By Reuters

October 8, 202511:35 PM UTCUpdated ago

A Microsoft logo is seen in Los Angeles, California U.S. November 7, 2017. REUTERS/Lucy Nicholson Purchase Licensing Rights, opens new tab

Oct 8 (Reuters) - Microsoft

(MSFT.O), opens new tab is partnering with Harvard Medical School to enhance its Copilot AI assistant with health content, as part of a broader effort to reduce its dependence on ChatGPT-maker OpenAI, the Wall Street Journal reported on Wednesday.

A major update of Copilot scheduled for release as soon as this month will be the first to reflect a new collaboration between Microsoft and Harvard Medical School, the report said, citing people familiar with the matter.

Sign up here.

Reuters could not immediately verify the report.

Microsoft and Harvard did not immediately respond to requests for comment.

Reporting by Rishabh Jaiswal and Rajveer Singh Pardesi in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles., opens new tab

ARYZTA AG - Special Call

Company Participants

Paul Meade - Head of Communications
Urs Jordi
Martin Huber - Group Chief Financial Officer

Conference Call Participants

Joern Iffert - UBS Investment Bank, Research Division
Jon Cox - Kepler Cheuvreux, Research Division

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to this ARYZTA update call. The call will have opening remarks by ARYZTA management and followed by Q&A. This call is being recorded. Now, I'd like to hand over to Paul Meade, Head of Investor Relations, to open the call. Please go ahead.

Paul Meade
Head of Communications

Thanks, Laura. Good morning, all, and welcome to today's update. I'm joined today by our Chairman and Interim CEO, Urs Jordi; and our CFO, Martin Huber. I would just like to remind everyone that the normal forward-looking statement of risks and uncertainties applies to all of today's discussions. I would now hand over to Urs.

Urs Jordi

Thank you, Paul. Good morning to everybody for joining this call. You did receive our ad hoc statement today morning. I think the message is understood, and I think we go directly into Q&A, Paul.

Paul Meade
Head of Communications

That's fine. Laura, can you ask folks if they have any questions on the ad hoc on the announcements, please?

Question-and-Answer Session

Operator

[Operator Instructions] The first question comes from Jorn Iffert of UBS.

Joern Iffert
UBS Investment Bank, Research Division

Just to double check, can you hear me?

Urs Jordi

Yes.

Joern Iffert
UBS Investment Bank, Research Division

Just a couple of questions from my side. The first one would be, please, I would take them one by one, if it's okay. There's a quite significant deviation in the second half EBITDA year-over-year versus your guidance of around, what is it, 10% plus/minus at least. Where exactly is this deviation coming from? This would be my

Recommended For You

, /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024 and January 6, 2025. Prior to its merger with Koito Manufacturing Co., Ltd., Cepton was an electronics company focused on the deployment of high performance, mass-market lidar technologies to deliver safety and autonomy across the Automotive and Smart Infrastructure markets. 

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Cepton, Inc. (CPTN) Misled Investors in Connection with the Company's Acquisition by Koito Manufacturing Co., Ltd.

The complaint alleges that in December 2023, Koito announced a bid to acquire Cepton for $3.17 per share in cash in a going private transaction. The transaction closed on January 7, 2025.

According to the complaint, defendants failed to disclose that: (i) Cepton had received a credible third-party bid valuing Cepton at more than double the Koito Acquisition; (ii) Cepton's Board of Directors failed to meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton's shareholders approve the Koito acquisition; and (iii) as a result, Cepton's shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito acquisition.

What Now: You may be eligible to participate in the class action against Cepton, Inc. Shareholders who wish to serve as lead plaintiff for the class must file their papers with the court by December 8, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. 

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. 

To be notified if a class action against Cepton, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome. 

SOURCE Robbins LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

CoreWeave Co-Founder and CEO Mike Intrator joins 'Mad Money' host Jim Cramer to talk quarterly results, the state of play in the AI space, recent acquisitions and more.

JPMorgan Chase & Co. (JPM - Free Report) closed the most recent trading day at $304.03, moving -1.19% from the previous trading session. This move lagged the S&P 500's daily gain of 0.58%.

Shares of the company witnessed a gain of 3.3% over the previous month, beating the performance of the Finance sector with its gain of 1.07%, and underperforming the S&P 500's gain of 3.68%.

Analysts and investors alike will be keeping a close eye on the performance of JPMorgan Chase & Co. in its upcoming earnings disclosure. The company's earnings report is set to go public on October 14, 2025. On that day, JPMorgan Chase & Co. is projected to report earnings of $4.83 per share, which would represent year-over-year growth of 10.53%. Simultaneously, our latest consensus estimate expects the revenue to be $44.66 billion, showing a 4.7% escalation compared to the year-ago quarter.

JPM's full-year Zacks Consensus Estimates are calling for earnings of $19.87 per share and revenue of $178.82 billion. These results would represent year-over-year changes of +0.61% and +0.71%, respectively.

Investors should also note any recent changes to analyst estimates for JPMorgan Chase & Co. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.14% higher. Currently, JPMorgan Chase & Co. is carrying a Zacks Rank of #3 (Hold).

Digging into valuation, JPMorgan Chase & Co. currently has a Forward P/E ratio of 15.49. This expresses a discount compared to the average Forward P/E of 16.79 of its industry.

It is also worth noting that JPM currently has a PEG ratio of 1.96. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Financial - Investment Bank stocks are, on average, holding a PEG ratio of 1.49 based on yesterday's closing prices.

The Financial - Investment Bank industry is part of the Finance sector. With its current Zacks Industry Rank of 28, this industry ranks in the top 12% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

, /PRNewswire/ -- NeoVolta Inc. (NASDAQ:NEOV) is moving quickly to scale its energy storage business, signing an asset purchase agreement for Neubau Energy's next-generation modular battery platform and adding Neubau's senior leadership team to its ranks. 

The transaction, finalized on October 1, 2025, is expected to close by October 15 and to be immediately accretive to both revenue and gross margins.

NeoVolta Expands Portfolio With Neubau Energy Acquisition, Targeting Higher Revenues and Margins

As part of the transaction, NeoVolta has appointed Amany Ibrahim as Chief Operating Officer and Thomas Enzendorfer as Chief Technology Officer. Michael Mendik, NeoVolta's previous COO, will remain with the company as Chief Product Officer.

Amany Ibrahim, co-founder and former Chief Strategy Officer at Neubau Energy, led product innovation and market expansion for its modular residential battery platform. She brings over a decade of operational experience in energy and infrastructure. Thomas Enzendorfer served as CEO of Neubau Energy in California and Managing Director in Vienna, overseeing solar manufacturing and distribution. His prior roles include Director of Solar Energy at Fronius USA and President of Soligent Distribution LLC.

A Platform Built for Speed

By integrating Neubau's modular energy storage technology, NeoVolta expects to accelerate its expansion across the residential storage market. Neubau's 30-minute installation systems will soon be available under the NeoVolta brand, cutting deployment costs by up to 75% and opening new channels for installers and electricians.

"Merging Neubau's talent and next-gen battery manufacturing platform is a significant milestone in executing our growth multi-channel strategy. As the transaction accelerates our residential energy storage market penetration, we expect it to be immediately accretive to revenue and gross margins," said Ardes Johnson, CEO of NeoVolta. "Neubau's technology portfolio and manufacturing know-how are expected to provide us tariff-free access to advanced battery technology. At Neubau, Amany has spearheaded strategy, product innovation, and market expansion and Thomas led manufacturing and distribution. We are excited they will strengthen our team and support our aggressive growth plans."

Deal Overview

The acquisition brings together Neubau's proprietary battery architecture and NeoVolta's growing distribution network, creating a platform designed for scale. Neubau's modular design, which is protected by more than a dozen patents, integrates inverters, batteries, and management software into a single, rapidly deployable system that one installer can set up in under 30 minutes.

Under the terms of the agreement, NeoVolta:

Paid $500,000 in cash and issued 200,000 restricted common shares at signing.
Will pay unit royalties of $10 per neuClick Battery Module sold for three years.
May issue up to 4 million additional restricted shares if Neubau-related revenue milestones are met before December 31, 2028.
NeoVolta expects the transaction to:

Strengthen its leadership with Neubau's senior executives joining key operational roles.
Reduce installation times by up to 75%, expanding access to new installer networks.
Add high energy-density ESS modules and modular battery patents to its portfolio.
Lessen exposure to 2026 tariffs through Neubau's Austrian manufacturing base.
Together, the integration is expected to accelerate NeoVolta's residential market reach, increase gross margins, and deepen the company's presence across both U.S. and international energy storage markets.

About Neubau Energy

Founded in 2023, Neubau Energy has developed one of the industry's most installer-friendly residential battery system with the highest energy density in its class. The company's truly modular architecture, protected by over a dozen patents, integrates batteries, inverter, battery management, and communications into a single unit that one person can install in under 30 minutes. The company's experienced team includes veterans from the energy storage, solar, and automotive industries who will continue driving innovation in operational and technology leadership roles as part of the combined organization. Neubau's Austrian manufacturing base provides a tariff-advantaged platform for the U.S. residential storage market. For more information visit: www.neubauenergy.com

About NeoVolta

NeoVolta is a leading innovator in energy storage solutions dedicated to advancing the future of clean energy. Founded to provide reliable, sustainable, and high-performance energy storage systems, the company has quickly established itself as a critical player in the industry. NeoVolta's flagship products are designed to meet the growing demand for efficient energy management in residential and commercial applications. With a focus on cutting-edge technology and strategic partnerships, NeoVolta is committed to driving progress in renewable energy and enhancing how the world stores and uses power. For more information visit: www.neovolta.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the acquisition of Neubau Energy assets, expected financial impacts, market opportunities, operational benefits, and anticipated closing timeline. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to, the ability to complete definitive documentation, satisfaction of closing conditions, integration challenges, market acceptance of combined offerings, realization of anticipated synergies, and other risks detailed in NeoVolta's SEC filings. The company undertakes no obligation to update forward-looking statements except as required by law. For additional risk factors, see Item 1A "Risk Factors" in the Company's most recent Form 10-K and subsequent Form 10-Q filings with the SEC.

Contacts

Investors David Barnard, Alliance Advisors IR [email protected]

415-433-3777

Media Email: [email protected]

800-364-5464

Disclosure:

1) The author of the Article, or members of the author's immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by,  NeoVolta Inc. Market Jar Media Inc. was paid $1,500 USD for the production and publishing of this article by  NeoVolta Inc.'s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.'s engagement by NeoVolta Inc.'s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-neov. 

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use (https://pressreach.com/terms-of-use/) and full legal disclaimer as set forth here (https://pressreach.com/disclaimer/). This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation, (collectively, "forward-looking statements"), which reflect management's expectations regarding  NeoVolta Inc.'s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to  NeoVolta Inc.'s industry; (b) market opportunity; (c)  NeoVolta Inc.'s business plans and strategies; (d) services that  NeoVolta Inc.. intends to offer; (e)  NeoVolta Inc.'s milestone projections and targets; (f)  NeoVolta Inc.'s expectations regarding receipt of approval for regulatory applications; (g)  NeoVolta Inc.'s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h)  NeoVolta Inc.'s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute  NeoVolta Inc.'s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c)  NeoVolta Inc.'s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e)  NeoVolta Inc.'s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of  NeoVolta Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a)  NeoVolta Inc.'s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact  NeoVolta Inc.'s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing  NeoVolta Inc.'s business operations (e) NeoVolta Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law,  NeoVolta Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does  NeoVolta Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither  NeoVolta Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of  NeoVolta Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of  NeoVolta Inc. or such entities and are not necessarily indicative of future performance of  NeoVolta Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

Read more investing news on PressReach.com.

Subscribe to the PressReach RSS feeds:

Featured News RSS feed
Investing News RSS feed
Daily Press Releases RSS feed
Trading Tips RSS feed
Investing Videos RSS feed
Follow PressReach on Twitter

Follow PressReach on TikTok

Follow PressReach on Instagram

Subscribe to us on Youtube

Contact

Media
[email protected]

SOURCE NeoVolta Inc

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Vancouver, British Columbia, Canada – October 8, 2025 – TheNewswire - GOAT Industries Ltd. (the “Company” or “GOAT”) (CSE: GOAT) (OTCQB: BGTTF) (FWB: 26B.F) is pleased to announce that its common shares have been approved for trading on the OTCQB Venture Market (the “OTCQB”), operated by the OTC Markets Group, effective as of market open on October 9, 2025. The Company will continue to trade under the symbol “BGTTF” on the OTCQB and “GOAT” on the Canadian Securities Exchange (“CSE”).

The uplisting to the OTCQB Venture Market marks a significant milestone in GOAT’s capital markets strategy and underscores the Company’s commitment to transparency, governance, and growth. This achievement enhances GOAT’s visibility and credibility through compliance with U.S. securities regulations and ongoing disclosure obligations, while improving liquidity and accessibility for U.S. investors by expanding market depth and trading volume. The OTCQB, recognized as a premier venture market for early-stage and developing companies that meet stringent financial reporting and governance standards, provides GOAT with a platform that promotes greater transparency, stronger corporate governance, and the ability to attract both institutional and retail investors across North America. Collectively, these benefits reinforce GOAT’s long-term growth objectives as the Company continues to build shareholder value and strengthen its presence in North American capital markets.

“Achieving OTCQB status is a significant milestone for GOAT,” said Kevin Cornish, Interim CEO. “This uplisting reflects our commitment to transparency, governance, and growth. We believe trading on the OTCQB will improve market visibility, enhance liquidity, and provide broader access to U.S. investors as we continue to execute on our business strategy.”

Existing shareholders are not required to take any action. GOAT Industries will continue to trade on the CSE under the symbol “GOAT” and remains subject to all applicable CSE and Canadian securities regulations.

ABOUT GOAT INDUSTRIES LTD.

GOAT is an investment issuer focused on investing in high-potential companies operating across a variety of industries and sectors. The goal of the Company is to generate maximum returns from its investments.

For more information about the Company, please visit https://www.goatindustries.co/. The Company’s final prospectus, financial statements and management's discussion and analysis, among other documents, are all available on its profile page on SEDAR+ at www.sedarplus.ca.

ON BEHALF OF THE BOARD OF DIRECTORS

Interim Chief Executive Officer                Kevin Cornish

Head Office                                Suite 2300, 550 Burrard Street, Vancouver, BC V6C 2B5

Telephone                                1-604-683-6498

Website                                www.goatindustries.co  

Email                                        [email protected]  

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, including, but not limited to, statements regarding the Company’s uplisting to the OTCQB Venture Market, the potential benefits of such uplisting, the Company’s business objectives, growth strategies, market visibility, liquidity, and future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, risks relating to the Company’s ability to maintain compliance with the OTCQB and CSE listing requirements, market conditions, investor interest, and general business, economic, competitive, political, and social uncertainties. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Canada Goose (GOOS - Free Report) closed the most recent trading day at $13.72, moving -1.29% from the previous trading session. This change lagged the S&P 500's daily gain of 0.58%.

Heading into today, shares of the high-end coat maker had lost 6.65% over the past month, lagging the Retail-Wholesale sector's loss of 2.75% and the S&P 500's gain of 3.68%.

Market participants will be closely following the financial results of Canada Goose in its upcoming release. The company is expected to report EPS of -$0.05, down 225% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $208.8 million, reflecting a 6.36% rise from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates project earnings of $0.99 per share and a revenue of $1.05 billion, demonstrating changes of +23.75% and +8.22%, respectively, from the preceding year.

It is also important to note the recent changes to analyst estimates for Canada Goose. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Canada Goose currently has a Zacks Rank of #3 (Hold).

From a valuation perspective, Canada Goose is currently exchanging hands at a Forward P/E ratio of 14.11. This represents a discount compared to its industry average Forward P/E of 17.84.

Also, we should mention that GOOS has a PEG ratio of 1.04. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Retail - Apparel and Shoes stocks are, on average, holding a PEG ratio of 2.38 based on yesterday's closing prices.

The Retail - Apparel and Shoes industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 72, positioning it in the top 30% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Emerson Electric (EMR - Free Report) closed at $132.94 in the latest trading session, marking a +1.1% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.58%.

Shares of the maker of process controls systems, valves and analytical instruments witnessed a loss of 0.42% over the previous month, trailing the performance of the Industrial Products sector with its gain of 0.74%, and the S&P 500's gain of 3.68%.

Analysts and investors alike will be keeping a close eye on the performance of Emerson Electric in its upcoming earnings disclosure. On that day, Emerson Electric is projected to report earnings of $1.62 per share, which would represent year-over-year growth of 9.46%. Meanwhile, the latest consensus estimate predicts the revenue to be $4.9 billion, indicating a 5.98% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6 per share and revenue of $18.06 billion, indicating changes of +9.29% and 0%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for Emerson Electric. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.06% increase. Emerson Electric is currently sporting a Zacks Rank of #3 (Hold).

In terms of valuation, Emerson Electric is currently trading at a Forward P/E ratio of 20.33. Its industry sports an average Forward P/E of 23.03, so one might conclude that Emerson Electric is trading at a discount comparatively.

We can also see that EMR currently has a PEG ratio of 2.29. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Manufacturing - Electronics stocks are, on average, holding a PEG ratio of 1.92 based on yesterday's closing prices.

The Manufacturing - Electronics industry is part of the Industrial Products sector. With its current Zacks Industry Rank of 151, this industry ranks in the bottom 39% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Agnico Eagle Mines (AEM - Free Report) ended the recent trading session at $169.57, demonstrating a +1.97% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.58%.

Shares of the gold mining company witnessed a gain of 8.86% over the previous month, beating the performance of the Basic Materials sector with its gain of 0.05%, and the S&P 500's gain of 3.68%.

The investment community will be paying close attention to the earnings performance of Agnico Eagle Mines in its upcoming release. The company is slated to reveal its earnings on October 29, 2025. It is anticipated that the company will report an EPS of $1.71, marking a 50% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $2.73 billion, up 26.52% from the year-ago period.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $7.14 per share and a revenue of $10.84 billion, signifying shifts of +68.79% and +30.81%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Agnico Eagle Mines. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 2.94% rise in the Zacks Consensus EPS estimate. Right now, Agnico Eagle Mines possesses a Zacks Rank of #1 (Strong Buy).

In terms of valuation, Agnico Eagle Mines is currently trading at a Forward P/E ratio of 23.29. This denotes a premium relative to the industry average Forward P/E of 16.47.

One should further note that AEM currently holds a PEG ratio of 1.11. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Mining - Gold industry had an average PEG ratio of 0.81.

The Mining - Gold industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 48, putting it in the top 20% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Citigroup (C - Free Report) ended the recent trading session at $96.70, demonstrating a -1.12% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.58%.

The stock of U.S. bank has risen by 0.47% in the past month, lagging the Finance sector's gain of 1.07% and the S&P 500's gain of 3.68%.

The investment community will be paying close attention to the earnings performance of Citigroup in its upcoming release. The company is slated to reveal its earnings on October 14, 2025. In that report, analysts expect Citigroup to post earnings of $1.87 per share. This would mark year-over-year growth of 23.84%. In the meantime, our current consensus estimate forecasts the revenue to be $21.01 billion, indicating a 3.4% growth compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates project earnings of $7.59 per share and a revenue of $84.74 billion, demonstrating changes of +27.56% and +4.44%, respectively, from the preceding year.

Investors should also take note of any recent adjustments to analyst estimates for Citigroup. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.21% higher within the past month. Citigroup currently has a Zacks Rank of #3 (Hold).

In terms of valuation, Citigroup is currently trading at a Forward P/E ratio of 12.89. Its industry sports an average Forward P/E of 16.79, so one might conclude that Citigroup is trading at a discount comparatively.

It is also worth noting that C currently has a PEG ratio of 0.85. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. C's industry had an average PEG ratio of 1.49 as of yesterday's close.

The Financial - Investment Bank industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 28, placing it within the top 12% of over 250 industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Grab Holdings Limited (GRAB - Free Report) ended the recent trading session at $6.36, demonstrating a +1.44% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.58%.

The stock of company has risen by 18.53% in the past month, leading the Computer and Technology sector's gain of 6.37% and the S&P 500's gain of 3.68%.

Market participants will be closely following the financial results of Grab Holdings Limited in its upcoming release. On that day, Grab Holdings Limited is projected to report earnings of $0.01 per share, which would represent no growth from the year-ago period. Our most recent consensus estimate is calling for quarterly revenue of $874.84 million, up 22.18% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $0.05 per share and revenue of $3.4 billion, which would represent changes of +266.67% and +21.65%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for Grab Holdings Limited. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 7.69% higher within the past month. Grab Holdings Limited is currently sporting a Zacks Rank of #2 (Buy).

Investors should also note Grab Holdings Limited's current valuation metrics, including its Forward P/E ratio of 134.36. For comparison, its industry has an average Forward P/E of 29.68, which means Grab Holdings Limited is trading at a premium to the group.

The Internet - Software industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 85, positioning it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Sprouts Farmers (SFM - Free Report) closed the most recent trading day at $104.38, moving +1.5% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.58%.

Shares of the natural and organic food retailer witnessed a loss of 24.39% over the previous month, trailing the performance of the Retail-Wholesale sector with its loss of 2.75%, and the S&P 500's gain of 3.68%.

The upcoming earnings release of Sprouts Farmers will be of great interest to investors. The company's earnings report is expected on October 29, 2025. The company is expected to report EPS of $1.16, up 27.47% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.22 billion, up 14.06% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $5.28 per share and a revenue of $8.93 billion, demonstrating changes of +40.8% and +15.66%, respectively, from the preceding year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Sprouts Farmers. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Sprouts Farmers holds a Zacks Rank of #2 (Buy).

Looking at its valuation, Sprouts Farmers is holding a Forward P/E ratio of 19.48. This valuation marks a discount compared to its industry average Forward P/E of 19.8.

Also, we should mention that SFM has a PEG ratio of 1.17. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Food - Natural Foods Products industry had an average PEG ratio of 1.16 as trading concluded yesterday.

The Food - Natural Foods Products industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 94, positioning it in the top 39% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Moderna (MRNA - Free Report) closed the most recent trading day at $27.92, moving +2.12% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.58%.

Prior to today's trading, shares of the biotechnology company had gained 11.73% outpaced the Medical sector's gain of 2.74% and the S&P 500's gain of 3.68%.

Market participants will be closely following the financial results of Moderna in its upcoming release. The company is predicted to post an EPS of -$1.95, indicating a 6600% decline compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $925.77 million, indicating a 50.28% decline compared to the corresponding quarter of the prior year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$9.59 per share and a revenue of $1.93 billion, representing changes of -8.12% and -40.37%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.15% increase. Moderna is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 90, positioning it in the top 37% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

In the latest trading session, Nice (NICE - Free Report) closed at $138.20, marking a +2.26% move from the previous day. This move outpaced the S&P 500's daily gain of 0.58%.

The software company's shares have seen a decrease of 5.72% over the last month, not keeping up with the Computer and Technology sector's gain of 6.37% and the S&P 500's gain of 3.68%.

Analysts and investors alike will be keeping a close eye on the performance of Nice in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $3.17, marking a 10.07% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $727.92 million, up 5.5% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $12.44 per share and a revenue of $2.93 billion, representing changes of +11.87% and +7%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for Nice. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Nice is currently a Zacks Rank #3 (Hold).

In the context of valuation, Nice is at present trading with a Forward P/E ratio of 10.87. This denotes a discount relative to the industry average Forward P/E of 29.68.

It is also worth noting that NICE currently has a PEG ratio of 0.96. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Internet - Software industry held an average PEG ratio of 2.22.

The Internet - Software industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 85, this industry ranks in the top 35% of all industries, numbering over 250.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

In the latest trading session, Monday.com (MNDY - Free Report) closed at $184.19, marking a +2.92% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day.

The project management software developer's shares have seen a decrease of 7.58% over the last month, not keeping up with the Computer and Technology sector's gain of 6.37% and the S&P 500's gain of 3.68%.

The investment community will be paying close attention to the earnings performance of Monday.com in its upcoming release. The company is expected to report EPS of $0.89, up 4.71% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $312.06 million, indicating a 24.33% upward movement from the same quarter last year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.97 per share and revenue of $1.23 billion, indicating changes of +13.43% and +26.09%, respectively, compared to the previous year.

Any recent changes to analyst estimates for Monday.com should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Monday.com is currently a Zacks Rank #5 (Strong Sell).

From a valuation perspective, Monday.com is currently exchanging hands at a Forward P/E ratio of 45.03. This signifies a premium in comparison to the average Forward P/E of 29.68 for its industry.

It is also worth noting that MNDY currently has a PEG ratio of 1.63. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Internet - Software industry currently had an average PEG ratio of 2.22 as of yesterday's close.

The Internet - Software industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 85, positioning it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

BioVie Inc. - Special Call

Company Participants

Cuong Viet Do - President, CEO & Director

Conference Call Participants

Craig Brelsford

Presentation

Craig Brelsford

Hello. This is Craig Brelsford with RedChip Companies. Thank you for joining today's event with BioVie, which trades on the NASDAQ under the ticker BIVI. With us today, we have Cuong Do, President and CEO of BioVie. We will begin with a brief presentation in a moment and then we will answer your questions. Submit your question at any time by using the Q&A tool at the bottom of the Zoom window.

Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Ligation Reform Act of 1995. All statements pertaining to future financial and/or operating results, along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements. Any statements that are not historical facts should also be considered forward-looking statements. Of course, forward-looking statements involve risks and uncertainties.

I now turn this webinar over to Cuong. Go ahead.

Cuong Viet Do
President, CEO & Director

Good afternoon, Craig. Thank you for joining. Good afternoon, everyone. Thank you for joining our update today. I'm very excited to share with you this afternoon some exciting progress at the company, right?

As you know, we have several clinical trials underway right now, which makes it -- I believe we have one of the most exciting biotech companies around with an exciting portfolio. You may know that we have a Parkinson's clinical trial that is underway. It is a Phase II trial, and now we can pick up -- enrollment has picked up relatively quickly within the last few weeks, and we can now project to be fully enrolled by the end of 2025. As a result

Recommended For You

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Trinseo PLC ("Trinseo" or the "Company") (NYSE: TSE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Trinseo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 6, 2025, Trinseo announced that it is indefinitely suspending its quarterly dividend and permanently closing its methyl methacrylate production operations in Rho, Italy, and its acetone cyanohydrin production operations in Porto Marghera, Italy. Trinseo said that its actions are aimed at further optimizing its operations, enhancing cash flow generation and strengthening long-term profitability. 

On this news, Trinseo's stock price fell $0.29 per share, or 12.21%, to close at $2.05 per share on October 7, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Skye and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 6, 2025, Skye issued a press release "announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody."  The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy." 

On this news, Skye's stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In